Patients of childbearing potential (i.e., women of childbearing potential and men with female partners of childbearing potential) who are unwilling to follow strict contraception requirements (including  reliable methods in combination:  non-hormonal, highly-reliable method [diaphragm, condoms with spermicidal foam or jelly, or sterilization] plus  additional reliable method [birth control pills, intrauterine device, contraceptive injections, or contraceptive patches]) before entry and throughout the study, up to and including the -day non-treatment follow-up period
Pregnancy or lactation at the time of registration; for women of childbearing potential, they must agree to use effective contraceptive methods such as condom/diaphragm and spermicidal foam, intrauterine device, or prescription birth control pills
Women of childbearing potential must practice contraception; females of childbearing potential: recommendation is for  effective contraceptive methods during the study; adequate forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, Depo Provera, or injectable contraceptives, intrauterine devices, and tubal ligation; male patients with female partners who are of childbearing potential: recommendation is for male and partner to use at least  effective contraceptive methods, as described above, prior to study entry and for at least  months after the last dose of study drug
Patients with reproductive potential who are unwilling to following contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives [birth control pills], contraceptive injections, intrauterine devices [IUD], double-barrier method [spermicidal jelly or foam with condoms or diaphragm], contraceptive patch, or surgical sterilization) throughout the study
For Phase I and II: Women of childbearing potential must practice contraception. Women considered not of childbearing potential include any of the following: no menses for at least  years or menses within  years but amenorrheic for at least  months and luteinizing hormone (LH) and follicular stimulating hormone (FSH) values within normal range (according to definition of postmenopausal for laboratory used) or bilateral oophorectomy or radiation castration and amenorrheic for at least  months. Females of childbearing potential should practice effective methods of contraception Effective methods of contraception include barrier methods (e.g., condoms, diaphragm), spermicidal jelly or foam, oral, depo provera, or injectable contraceptives, intrauterine devices, tubal ligation, and abstinence. Male patients with female partners who are of childbearing potential should also practice contraception.
Women of childbearing potential should be advised to avoid becoming pregnant while on therapy with Ruxolitinib and for  days after the last dose and practice effective methods of contraception. Men should be advised not to father a child while receiving treatment with Ruxolitinib and for  days after the last dose. Effective methods of contraception for this study include barrier methods (e.g., condoms, diaphragm); spermicidal jelly or foam; oral, depo provera, or injectable hormonal contraceptives; intrauterine devices; tubal ligation; and abstinence.
Women of childbearing age must have documentation of a negative pregnancy test and agreed that they or their partner use an effective contraceptive method such as condom/diaphragm and spermicidal foam, non-stainless-steel intrauterine device, or prescription birth control pills
Patients of childbearing potential must practice contraception; females of childbearing potential: recommendation is for  effective contraceptive methods during the study; adequate forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation; male patients with female partners who are of childbearing potential: recommendation is for male and partner to use at least  effective contraceptive methods, as described above, during the study; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
WOCBP must practice contraception. Acceptable methods of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, tubal ligations, and abstention
Women of childbearing potential should be advised to avoid becoming pregnant with an adequate method of contraception (barrier or hormonal methods) and men should be advised to not father a child while receiving treatment with azacitidine; all men and women of childbearing potential must use acceptable methods of birth control throughout the study as described below: women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment; men should use adequate birth control for at least  days after the last administration of sorafenib; post-menopausal women (defined as no menses for at least one year) and surgically sterilized women are not required to undergo a pregnancy test; females of childbearing potential: recommendation is for  effective contraceptive methods during the study; adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, Depo-Provera, or injectable contraceptives, intrauterine devices, and tubal ligation; male patients with female partners who are of childbearing potential: recommendation is for male and partner to use at least  effective contraceptive methods, as described above, during the study
Men of reproductive potential who do not agree that they or their partner will use an effective contraceptive method such as condom/diaphragm and spermicidal foam, intrauterine device (IUD), or prescription birth control pills
Patients with reproductive potential who are unwilling to following contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives [birth control pills], contraceptive injections, intrauterine devices [IUD], double-barrier method [spermicidal jelly or foam with condoms or diaphragm], contraceptive patch, or surgical sterilization) throughout the study
For female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ  forms of adequate birth control measures, including at least  barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least  days after the last administration of BAX. Other acceptable contraceptive measures include birth control pills/patches or intrauterine devices
For male subjects, the subject must agree to use adequate contraceptive measures including at least  barrier method (eg, condom with spermicidal jelly or foam and [for the female partner] diaphragm with spermicidal jelly or foam, birth control pills/patches, or intrauterine device) and abstain from sperm donation throughout the course of the study and for at least  days after the last administration of BAX
Women of childbearing potential must practice contraception; females of childbearing potential: recommendation is for  effective contraceptive methods during the study; adequate forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation; male patients with female partners who are of childbearing potential: recommendation is for male and partner to use at least  effective contraceptive methods during the study
Women of childbearing potential and male participants must agree to use a medically effective means of birth control, such as condom/diaphragm and spermicidal foam, intrauterine device (IUD), or prescription birth control pills, throughout their participation in the treatment phase of the study
Women of childbearing potential must practice contraception; females of childbearing potential: recommendation is for  effective contraceptive methods during the study; adequate forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation; male patients with female partners who are of childbearing potential: recommendation is for male and partner to use at least  effective contraceptive methods, as described above, during the study
Women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment; all men and women of childbearing potential must use acceptable methods of birth control throughout the study as described below:\r\n* Females of childbearing potential: recommendation is for  effective contraceptive methods during the study; adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation\r\n* Male patients with female partners who are of childbearing potential: recommendation is for male and partner to use at least  effective contraceptive methods, as described above, during the study or to abstain
Women of childbearing potential must use an effective contraceptive method such as condom/diaphragm and spermicidal foam, intrauterine device (IUD), or prescription birth control pills; a negative pregnancy test must be obtained prior to study enrollment or waiver signed
Women of childbearing potential (WOCBP) must practice  effective methods of birth control during the course of the study; male patients who are partners of WOCBP should also practice an effective method of contraception; effective methods of birth control include diaphragm or condoms with spermicidal foam or jelly, birth control pills (BCPs), injections or patches, intra-uterine devices (IUDs) and surgical sterilization
Women of childbearing potential and male participants must use an effective contraceptive method such as condom/diaphragm and spermicidal foam, intrauterine device, or prescription birth control pills
Women of childbearing potential must agree to use acceptable methods of birth control starting with the screening visit and up to  days after the last dose of study treatment. Recommendation is for  effective contraceptive methods during the study. Adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation.
